Group 1 - The core focus of the company is on the development of oncology therapies [1] - As of December 19, 2025, the company's stock price experienced a notable increase of 5.52% in a single day [1] - Financial reports indicate that the company has generated zero revenue and has a negative net profit [1]

Core Viewpoint - Apollomics Inc. reported its financial results for the first half of 2025, highlighting a significant reduction in net loss compared to the same period in 2024, alongside ongoing development of its oncology drug candidates [1][7]. Financial Performance - Cash, cash equivalents, bank deposits, and money market funds as of June 30, 2025, were $2.1 million, down from $9.8 million as of December 31, 2024 [7]. - Research and development (R&D) expenses for the first half of 2025 were $4.6 million, a decrease from $16.9 million in the first half of 2024 [7]. - General and administrative (G&A) expenses were $14.5 million for the first half of 2025, compared to $10.2 million in the same period of 2024 [7]. - The net loss for the first half of 2025 was $(12.5) million, or $(11.37) per basic and diluted share, compared to a net loss of $(35.2) million, or $(37.53) per basic and diluted share, for the first half of 2024 [7][14]. Asset and Liability Overview - Total assets as of June 30, 2025, were $11.1 million, down from $13.1 million as of December 31, 2024 [10]. - Current liabilities increased to $10.5 million as of June 30, 2025, from $7.4 million as of December 31, 2024 [10]. - The company reported net liabilities of $(4.4) million as of June 30, 2025, compared to net assets of $4.9 million at the end of 2024 [11]. Company Overview - Apollomics Inc. is focused on developing oncology therapies, with its lead program being vebreltinib (APL-101), a selective c-Met inhibitor currently in a Phase 2 clinical trial [3].

Group 1 - The core viewpoint of the articles highlights the financial performance and growth potential of Crown BioMed-A (APLM), showcasing a significant increase in revenue and net profit [1][2]. - As of December 31, 2023, Crown BioMed-A reported total revenue of $71.604 million, representing a year-over-year growth of 62.06% [1]. - The company recorded a net profit attributable to shareholders of $172.6 million, which is a 28.33% increase compared to the previous year [2]. Group 2 - Crown BioMed Limited is an innovative biotechnology company focused on exploring and developing cancer therapies that may combine with other treatment options, utilizing the immune system and targeting specific molecular signaling pathways to inhibit cancer [2]. - The company operates in both the United States and China, believing it has favorable conditions to leverage collaborations with other biotechnology firms in the East and West [2]. - Since its establishment in 2015, under the leadership of an experienced management team, the company has developed a pipeline consisting of ten oncology-focused drug candidates across twelve projects, with five candidates currently in clinical stages [2].

Core Insights - Apollomics Inc. has entered into a settlement agreement with TWVC Goldlink Partners Investment Limited and TWVC Panglin Group Investment Limited to resolve litigation related to preferred share redemption claims before its merger with Maxpro Capital Acquisition Corporation in 2023 [1][2] Financial Summary - The settlement agreement requires Apollomics to pay a total of US$5 million in cash to TWVC, to be paid in installments over two years, along with approximately US$879,757.78 in legal expenses [2] - The original damages claimed by TWVC were approximately US$40 million, as disclosed in the Form 20-F filed in April 2025 [2] Company Overview - Apollomics Inc. is a clinical-stage biopharmaceutical company focused on developing oncology therapies that can be combined with other treatments to target specific molecular pathways and harness the immune system [3] - The company's lead program is vebreltinib (APL-101), a selective c-Met inhibitor for treating non-small cell lung cancer and other advanced tumors with c-Met alterations, currently in a Phase 2 multicohort clinical trial [3]

Core Points - Apollomics Inc. announced changes to its board of directors, including the resignation of Mr. Po-Jen Hsueh and the appointment of Dr. Ya-Chi (Claudia) Huang to fill the vacancy [1][2] - The current board now consists of seven members, with Dr. Huang also taking over Mr. Hsueh's roles on the Audit Committee and Nominating and Corporate Governance Committee [2] - Dr. Huang brings extensive experience in biotechnology investment and corporate governance, having previously worked at Maxpro Ventures and Diamond Biofund [3][4][5] Company Overview - Apollomics Inc. is a clinical-stage biopharmaceutical company focused on developing oncology therapies that leverage the immune system and target specific molecular pathways [7] - The company's lead program is vebreltinib (APL-101), a selective c-Met inhibitor currently in a Phase 2 clinical trial for non-small cell lung cancer and other advanced tumors [7]

Core Points - Apollomics Inc. announced changes to its board of directors, with Mr. Po-Jen Hsueh resigning and Dr. Ya-Chi (Claudia) Huang appointed to fill the vacancy [1][2] - The current board now consists of seven members, including five independent directors [2] - Dr. Huang has extensive experience in biotechnology investment and corporate governance, previously serving in significant roles in the biopharmaceutical industry [3][4][5] Board Changes - Mr. Po-Jen Hsueh resigned from the board on November 16, 2025, with no disagreements reported [1] - Dr. Ya-Chi (Claudia) Huang was appointed to the board and will also serve on the Audit Committee and Nominating and Corporate Governance Committee [2] - The board now includes Hung-Wen (Howard) Chen (Chairman), Hong-Jung (Moses) Chen, Yi-Kuei Chen, Hsien-Shu Tsai, Yi-An Chu, Chen-Huan Jan, and Dr. Huang [2] New Director's Background - Dr. Huang is currently the Assistant Vice President at Maxpro Ventures, leading investment activities and managing post-investment operations [4] - Previously, she was an Investment Manager at Diamond Biofund, where she oversaw multiple investments and contributed to the fund's IPO in 2023 [5] - Dr. Huang has a strong scientific background, with research published in notable journals and awards for her doctoral work [6] Company Overview - Apollomics Inc. focuses on developing oncology therapies, with its lead program being vebreltinib (APL-101), a selective c-Met inhibitor for non-small cell lung cancer [7]

Core Points - Apollomics Inc. has successfully appealed a delisting notice from Nasdaq and will continue to be listed on the Nasdaq Stock Market [1] - The company is focused on developing therapies for resistant and refractory cancers, with its lead candidate being vebreltinib (APL-101), a selective c-Met inhibitor [2] Group 1 - Apollomics Inc. is a late-stage clinical biopharmaceutical company based in California, dedicated to developing various candidate oncology drugs [1] - The Nasdaq listing qualification department has determined that Apollomics meets the requirements for continued listing, leading to the cancellation of the scheduled appeal hearing [1] - The company's securities will continue to trade on the Nasdaq Stock Market [1] Group 2 - Apollomics is currently conducting Phase II multi-cohort clinical trials for vebreltinib, targeting non-small cell lung cancer and other advanced tumors with c-Met gene alterations [2] - The company aims to explore and develop cancer therapies that leverage the human immune system and target specific molecular pathways [2]

Core Points - Apollomics Inc. has successfully appealed a delisting notification from Nasdaq, resulting in the cancellation of the scheduled hearing and the continuation of its listing on the Nasdaq Stock Market [1] - The company is focused on developing oncology therapies, particularly its lead program vebreltinib (APL-101), a selective c-Met inhibitor for non-small cell lung cancer [2] Company Overview - Apollomics Inc. is a clinical-stage biopharmaceutical company based in California, specializing in oncology drug development aimed at treatment-resistant cancers [2] - The lead drug candidate, vebreltinib, is currently undergoing a Phase 2 multicohort clinical trial in the United States and other countries [2]

Core Viewpoint - Apollomics Inc. is a clinical-stage biotechnology company focused on developing innovative cancer therapies, particularly for patients with limited treatment options, and is currently advancing its lead candidate APL-101 (vebreltinib) through global clinical trials [1][3]. Group 1: Company Overview - Apollomics has 9 drug candidates in its pipeline, with 6 in clinical development targeting challenging cancers such as lung cancer and brain cancer [1]. - The company employs a strategy that combines targeted therapies, immuno-oncology, and innovative mechanisms of action to overcome resistance and achieve clinically meaningful efficacy [1]. Group 2: Recent Developments - On August 28, 2025, Apollomics announced plans to terminate all clinical trial activities related to APL-101 due to financial issues and sought shareholder approval for liquidation [2]. - Following a PIPE investment of $4.1 million on September 3, 2025, the company appointed a new board and management team, including Howard Chen as CEO and Alex Chen as COO [2]. Group 3: Clinical Trials and Future Plans - After securing additional funding and a new management team, Apollomics canceled its liquidation plans and will continue its existing operations, including the global development of APL-101 [3]. - The company is committed to completing the SPARTA clinical trials for APL-101, which are crucial for maximizing its therapeutic potential across various tumor types and supporting regulatory submissions in major markets [4]. - Apollomics plans to leverage its partnerships in China to advance regulatory submissions for APL-101 in emerging markets outside of Southeast Asia and the Middle East [4]. Group 4: Workforce and Operations - Apollomics currently has 12 full-time employees, with plans to increase the workforce to 15 by October 31, 2025, while also reducing staff in mainland China and reallocating resources to the U.S. and Taiwan [4].

Core Points - Trading in Apollomics Inc. Class A ordinary shares and warrants will resume on October 15, 2025, at 9:00 a.m. and 9:05 a.m. Eastern Time respectively [1] - Trading was previously halted on September 17, 2025, at 2:37:17 p.m. Eastern Time [1] Company Information - Apollomics Inc. is listed on the Nasdaq Stock Market under the symbols APLM for Class A ordinary shares and APLMW for warrants [1] - For further information, stakeholders are encouraged to contact the company directly or check the Nasdaq website [2]